

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>ISLAND PHARMACEUTICALS LIMITED</b>
<b>ABN</b>	<b>48 641 183 842</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	MR ALBERT HANSEN
<b>Date of last notice</b>	13 April 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	2. Kesa Partners Inc - President and controller
<b>Date of change</b>	18 November 2021
<b>No. of securities held prior to change</b>	1. 400,000 unlisted options exercisable at \$0.3625 each on or before 30/04/2024 - escrowed for 24 months from the date of listing. 2. 10,837,367 fully paid ordinary shares - escrowed for 24 months from date of listing. 23,030 unlisted options exercisable at \$0.373 each on or before 04/04/2023 - escrowed for 24 months from date of listing.
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	2. 100,000
<b>Number disposed</b>	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$0.25 per fully paid ordinary share

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 400,000 unlisted options exercisable at \$0.3625 each on or before 30/04/2024 – escrowed for 24 months from the date of listing.</li> <li>2. 10,837,367 fully paid ordinary shares – escrowed for 24 months from date of listing. 100,000 fully paid ordinary shares. 23,030 unlisted options exercisable at \$0.373 each on or before 04/04/2023 – escrowed for 24 months from date of listing.</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issued in lieu of Director's fees for the period 1/10/2020 to 13/04/2021 at \$0.25 per share as approved by shareholders at the AGM held on 17 November 2021.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	-
<b>Nature of interest</b>	-
<b>Name of registered holder (if issued securities)</b>	-
<b>Date of change</b>	-
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	-
<b>Interest acquired</b>	-
<b>Interest disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	-
<b>Interest after change</b>	-

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.